Clinicopathological and Prognostic Significance of PRMT5 in Cancers: A System Review and Meta-Analysis

Purpose Since protein arginine methyltransferase 5 (PRMT5) is abnormally expressed in various tumors, in this study we aim to assess the association between PRMT5 and clinicopathological and prognostic features. Methods Electronic databases including PubMed, Web of Science, Scopus, ScienceDirect, an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhenzhen Liang PhD, Lianchang Liu PhD, Chaowei Wen PhD, Heya Jiang MSci, Tianxia Ye MSci, Shumei Ma PhD, Xiaodong Liu PhD
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c236a6eeb6b04789ba237f234499fb0a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c236a6eeb6b04789ba237f234499fb0a
record_format	dspace
spelling	oai:doaj.org-article:c236a6eeb6b04789ba237f234499fb0a2021-11-11T23:03:45ZClinicopathological and Prognostic Significance of PRMT5 in Cancers: A System Review and Meta-Analysis1073-274810.1177/10732748211050583https://doaj.org/article/c236a6eeb6b04789ba237f234499fb0a2021-10-01T00:00:00Zhttps://doi.org/10.1177/10732748211050583https://doaj.org/toc/1073-2748Purpose Since protein arginine methyltransferase 5 (PRMT5) is abnormally expressed in various tumors, in this study we aim to assess the association between PRMT5 and clinicopathological and prognostic features. Methods Electronic databases including PubMed, Web of Science, Scopus, ScienceDirect, and the Cochrane Library were searched until July 25, 2021. The critical appraisal of the eligible studies was performed using the Newcastle–Ottawa Quality Assessment Scale. Pooled hazard ratios (HR) and pooled odds ratios (OR) were calculated to assess the effect. Engauge Digitizer version 12.1, STATA version 15.1, and R version 4.0.5 were used to obtain and analysis the data. Results A total of 32 original studies covering 15,583 patients were included. In our data, it indicated that high level of PRMT5 was significantly correlated with advanced tumor stage (OR = 2.12, 95% CI: 1.22-3.70, P =.008; I 2 = 80.7%) and positively correlated with poor overall survival (HR = 1.59, 95% CI: 1.46-1.73, P < .001; I 2 = 50%) and progression-free survival (HR = 1.53, 95% CI: 1.24-1.88, P < .001; I 2 = 0%). In addition, sub-group analysis showed that high level of PRMT5 was associated with poor overall survival for such 5 kinds of cancers as hepatocellular carcinoma, pancreatic cancer, breast cancer, gastric cancer, and lung cancer. Conclusion For the first time we found PRMT5 was pan-cancerous as a prognostic biomarker and high level of PRMT5 was associated with poor prognosis for certain cancers.Zhenzhen Liang PhDLianchang Liu PhDChaowei Wen PhDHeya Jiang MSciTianxia Ye MSciShumei Ma PhDXiaodong Liu PhDSAGE PublishingarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Control, Vol 28 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Zhenzhen Liang PhD Lianchang Liu PhD Chaowei Wen PhD Heya Jiang MSci Tianxia Ye MSci Shumei Ma PhD Xiaodong Liu PhD Clinicopathological and Prognostic Significance of PRMT5 in Cancers: A System Review and Meta-Analysis
description	Purpose Since protein arginine methyltransferase 5 (PRMT5) is abnormally expressed in various tumors, in this study we aim to assess the association between PRMT5 and clinicopathological and prognostic features. Methods Electronic databases including PubMed, Web of Science, Scopus, ScienceDirect, and the Cochrane Library were searched until July 25, 2021. The critical appraisal of the eligible studies was performed using the Newcastle–Ottawa Quality Assessment Scale. Pooled hazard ratios (HR) and pooled odds ratios (OR) were calculated to assess the effect. Engauge Digitizer version 12.1, STATA version 15.1, and R version 4.0.5 were used to obtain and analysis the data. Results A total of 32 original studies covering 15,583 patients were included. In our data, it indicated that high level of PRMT5 was significantly correlated with advanced tumor stage (OR = 2.12, 95% CI: 1.22-3.70, P =.008; I 2 = 80.7%) and positively correlated with poor overall survival (HR = 1.59, 95% CI: 1.46-1.73, P < .001; I 2 = 50%) and progression-free survival (HR = 1.53, 95% CI: 1.24-1.88, P < .001; I 2 = 0%). In addition, sub-group analysis showed that high level of PRMT5 was associated with poor overall survival for such 5 kinds of cancers as hepatocellular carcinoma, pancreatic cancer, breast cancer, gastric cancer, and lung cancer. Conclusion For the first time we found PRMT5 was pan-cancerous as a prognostic biomarker and high level of PRMT5 was associated with poor prognosis for certain cancers.
format	article
author	Zhenzhen Liang PhD Lianchang Liu PhD Chaowei Wen PhD Heya Jiang MSci Tianxia Ye MSci Shumei Ma PhD Xiaodong Liu PhD
author_facet	Zhenzhen Liang PhD Lianchang Liu PhD Chaowei Wen PhD Heya Jiang MSci Tianxia Ye MSci Shumei Ma PhD Xiaodong Liu PhD
author_sort	Zhenzhen Liang PhD
title	Clinicopathological and Prognostic Significance of PRMT5 in Cancers: A System Review and Meta-Analysis
title_short	Clinicopathological and Prognostic Significance of PRMT5 in Cancers: A System Review and Meta-Analysis
title_full	Clinicopathological and Prognostic Significance of PRMT5 in Cancers: A System Review and Meta-Analysis
title_fullStr	Clinicopathological and Prognostic Significance of PRMT5 in Cancers: A System Review and Meta-Analysis
title_full_unstemmed	Clinicopathological and Prognostic Significance of PRMT5 in Cancers: A System Review and Meta-Analysis
title_sort	clinicopathological and prognostic significance of prmt5 in cancers: a system review and meta-analysis
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/c236a6eeb6b04789ba237f234499fb0a
work_keys_str_mv	AT zhenzhenliangphd clinicopathologicalandprognosticsignificanceofprmt5incancersasystemreviewandmetaanalysis AT lianchangliuphd clinicopathologicalandprognosticsignificanceofprmt5incancersasystemreviewandmetaanalysis AT chaoweiwenphd clinicopathologicalandprognosticsignificanceofprmt5incancersasystemreviewandmetaanalysis AT heyajiangmsci clinicopathologicalandprognosticsignificanceofprmt5incancersasystemreviewandmetaanalysis AT tianxiayemsci clinicopathologicalandprognosticsignificanceofprmt5incancersasystemreviewandmetaanalysis AT shumeimaphd clinicopathologicalandprognosticsignificanceofprmt5incancersasystemreviewandmetaanalysis AT xiaodongliuphd clinicopathologicalandprognosticsignificanceofprmt5incancersasystemreviewandmetaanalysis
_version_	1718431373701677056

Clinicopathological and Prognostic Significance of PRMT5 in Cancers: A System Review and Meta-Analysis

Ejemplares similares